New Keppra XR data highlight its role for patients with partial-onset seizures

December 09, 2008

UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR™ (levetiracetam) extended-release tablets comparing tolerability vs. levetiracetam immediate release and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society in Seattle.

Keppra XR was approved by the U.S. Food and Drug Administration in September 2008 for use as adjunctive treatment for people with partial-onset seizures who are 16 years of age and older.

"In this new meta-analysis, patients taking Keppra XR experienced fewer nervous system side effects than those taking the same dose of twice daily levetiracetam," said James Zackheim, Medical Director, CNS, UCB. "Keppra XR is the only once-daily, extended-release formulation of levetiracetam, and there is no generic alternative available."

Summary of Keppra XR Data Presented at 2008 AES Annual Meeting

Safety Profile of Levetiracetam Extended Release Compared to Immediate Release: An Indirect Comparison Using a Meta-Analytic Approach

Researchers conducted a meta-analysis of Phase III data to determine whether Keppra XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. According to the meta-analysis, patients taking Keppra XR once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily. Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm (Abstract 3.243)
Florent Richy, MPH, PhD, Soutrik Banerjee, MD, PhD, Christophe Gervasoni, MS, Patricia Grossman, PharmD, MBA, Sandra Helmers, MD
UCB Pharma, Inc.; University of Liège, Belgium; Joseph Fourier University, France; Stendhal University, France; Emory University Hospital, USA

Single Dose Bioequivalence between Levetiracetam 2 x 750 mg XR Tablets and 3 x 500 mg XR Tablets and Food Effect on 2 x 750 mg XR Tablets in Healthy Subjects

This study demonstrated that an investigational 750 mg tablet strength of Keppra XR is bioequivalent to the approved 500 mg tablet when these are each combined to achieve a 1,500 mg dose. Results show that a single dose of 2 x 750 mg Keppra XR tablets was bioequivalent to a 3 x 500 mg single dose of Keppra XR in healthy adults, and that food intake did not significantly modify Keppra XR 2 x 750 mg disposition. Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm (Abstract 3.239)
Christian Otoul, Elisabeth Rouits, Ingrid Burton, Evelyne Guénolé, Mona Troenaru, Ans Valgaeren, Pierre Boulanger, Maria Laura Sargentini-Maier
UCB Pharma SA, Braine-L'Alleud, Belgium; Depar™ent of Pharmacokinetics, SGS Life Science Services, Wavre, Belgium; Therapharm Recherches, Caen, France

Additional Keppra XR Data Presented at 2008 AES Annual Meeting:
Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm (Abstract 3.247)
Elisabeth Rouits, M. Lovern, Maria Laura Sargentini-Maier and Armel Stockis
UCB Pharma, Braine-l'Alleud, Belgium
Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm (Abstract 3.25)
Rik Schoemaker, Eric Snoeck, Armel Stockis, Christian Otoul, Maria Laura Sargentini-Maier
Exprimo NV, Mechelen, Belgium; Pharmacometrics Depar™ent, UCB Pharma SA, Braine-l'Alleud, Belgium
Poster Session 3, Monday, December 8, 8:00 am - 1:30 (Abstract 3.263)
Ans Valgaeren, Nathalie Toublanc, Ingrid Burton, Sandrine Gelu-Mantoulet, Mona Troenaru, Christian Otoul, Maria Laura Sargentini-Maier, Armel Stockis
UCB Pharma SA, Braine-L'Alleud, Belgium; Depar™ent of Pharmacokinetics, SGS Life Science Services, Wavre, Belgium; Therapharm Recherches, Caen, France

Keppra XR cannot be substituted with any IR levetiracetam or any other antiepileptic medication at the pharmacy counter without a physician's approval.
Important Safety Information

Keppra XR™ extended-release tablets are indicated as adjunctive therapy in the trea™ent of partial onset seizures in patients 16 years of age and older with epilepsy.

Keppra XR™ causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR™ in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR™ are expected to be similar to those seen in patients receiving immediate-release Keppra® tablets.

Keppra® immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra® in combination with other AEDs were somnolence, asthenia, infection and dizziness.

Keppra XR™ should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient's renal function status. In patients with end-stage renal disease on dialysis, it is recommended that immediate-release Keppra® be used instead of Keppra XR™.

For full prescribing information, please see

In order to ensure patient access to this valuable medication in the U.S., UCB is initiating a co-pay support program. For more information, contact U.S. UCB Medical Information at 1-866-822-0068 (press 9).

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million people in the U.S.--making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Forty percent of patients taking only one AED continue to experience seizures, and approximately 30% of patients taking adjunctive therapy continue to experience seizures. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit,, or

About UCB

UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol: UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more information about UCB, visit

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

UCB Group

Related Data Articles from Brightsurf:

Keep the data coming
A continuous data supply ensures data-intensive simulations can run at maximum speed.

Astronomers are bulging with data
For the first time, over 250 million stars in our galaxy's bulge have been surveyed in near-ultraviolet, optical, and near-infrared light, opening the door for astronomers to reexamine key questions about the Milky Way's formation and history.

Novel method for measuring spatial dependencies turns less data into more data
Researcher makes 'little data' act big through, the application of mathematical techniques normally used for time-series, to spatial processes.

Ups and downs in COVID-19 data may be caused by data reporting practices
As data accumulates on COVID-19 cases and deaths, researchers have observed patterns of peaks and valleys that repeat on a near-weekly basis.

Data centers use less energy than you think
Using the most detailed model to date of global data center energy use, researchers found that massive efficiency gains by data centers have kept energy use roughly flat over the past decade.

Storing data in music
Researchers at ETH Zurich have developed a technique for embedding data in music and transmitting it to a smartphone.

Life data economics: calling for new models to assess the value of human data
After the collapse of the blockchain bubble a number of research organisations are developing platforms to enable individual ownership of life data and establish the data valuation and pricing models.

Geoscience data group urges all scientific disciplines to make data open and accessible
Institutions, science funders, data repositories, publishers, researchers and scientific societies from all scientific disciplines must work together to ensure all scientific data are easy to find, access and use, according to a new commentary in Nature by members of the Enabling FAIR Data Steering Committee.

Democratizing data science
MIT researchers are hoping to advance the democratization of data science with a new tool for nonstatisticians that automatically generates models for analyzing raw data.

Getting the most out of atmospheric data analysis
An international team including researchers from Kanazawa University used a new approach to analyze an atmospheric data set spanning 18 years for the investigation of new-particle formation.

Read More: Data News and Data Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to